...
机译:Rituximab加入Lenalidomide在需要一线治疗的滤泡淋巴瘤患者中的短期
Oncol Inst Southern Switzerland Div Med Oncol Bellinzona Switzerland;
SAKK Coordinating Ctr Bern Switzerland;
European Inst Oncol IRCCS Clin Hematooncol Milan Italy;
Oslo Univ Hosp Dept Oncol Oslo Norway;
Kantonsspital Graubunden Med Oncol &
Hematol Chur Switzerland;
Spital Thun Simmenthal Div Oncol Thun Switzerland;
Karolinska Inst Unit Hematol Dept Med Huddinge Stockholm Sweden;
Kantonsspital St Gallen Oncol Hematol St Gallen Switzerland;
Norrlands Univ Sjukhus Dept Oncol Umea Sweden;
Rigshosp Dept Hematol Copenhagen Denmark;
Uppsala Univ Hosp Oncol Uppsala Sweden;
IRCCS San Raffaele Sci Inst Unit Lymphoid Malignancies Milan Italy;
Med Univ Clin Dept Oncol Hematol Liestal Switzerland;
Luzerner Kantonsspital Dept Oncol Luzern Switzerland;
Univ Hosp North Norway Dept Oncol Tromso Norway;
Kantonsspital Aarau Div Hematol Oncol Aarau Switzerland;
Kantonsspital Olten Dept Med Oncol Olten Switzerland;
Univ Hosp Basel Dept Oncol Basel Switzerland;
Univ Hosp Basel Inst Pathol Basel Switzerland;
SAKK Coordinating Ctr Bern Switzerland;
SAKK Coordinating Ctr Bern Switzerland;
SAKK Coordinating Ctr Bern Switzerland;
Oncol Inst Southern Switzerland Div Med Oncol Bellinzona Switzerland;
机译:Rituximab加入Lenalidomide在需要一线治疗的滤泡淋巴瘤患者中的短期
机译:一线利妥昔单抗联合化疗后滤泡性非霍奇金淋巴瘤患者利妥昔单抗作为维持治疗的成本效益
机译:放射疗法加里妥昔单抗作为局部滤泡淋巴瘤的一线方案
机译:幼稚艾滋病毒感染患者的两种第一线推荐的抗逆转录病毒方案:efavirenz为基于Lopinavir-Ritonavir的HAART
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:比较在滤泡性淋巴瘤患者中利妥昔单抗维持和放射免疫治疗巩固与一线治疗后观察的成本效益
机译:Rituximab加入Lenalidomide在需要一线治疗的滤泡淋巴瘤患者中的短期